Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Myriad Genetics, Inc. < Previous 1 2 3 Next > Myriad Genetics Advances Prostate Cancer Care with Addition of Absolute Risk Reduction to Prolaris® August 15, 2023 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN Myriad Genetics and Intermountain Health Participate in ComboMATCH, a National Clinical Trial to Advance Cancer Treatment August 08, 2023 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN Myriad Genetics Announces Enhancements to the GeneSight® Test to Personalize Mental Health Medication Treatment Decisions Based on Smoking Status August 07, 2023 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN Myriad Genetics Reports Second Quarter 2023 Financial Results and Reaffirms 2023 Revenue and Adjusted EPS Guidance; Generates the Fourth Consecutive Quarter of Double-Digit Year-Over-Year Testing Volume Growth August 03, 2023 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN Myriad Genetics to Release Second Quarter Financial Results on Aug. 3, 2023 July 27, 2023 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN Myriad Genetics Announces Inclusion of Breast Density to MyRisk® with RiskScore® Breast Cancer Risk Assessment July 24, 2023 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN Myriad Genetics Announces New $90 Million Asset-Based Credit Facility July 06, 2023 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN Myriad Genetics Announces Research Collaboration to use Minimal Residual Disease Testing Platform June 12, 2023 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN Myriad Genetics to Participate in Goldman Sachs Healthcare Conference June 07, 2023 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN Myriad Genetics Highlights Latest Oncology Portfolio Advancements and New Data at ASCO 2023 June 01, 2023 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN Adam Brufsky, MD, PhD, FACP Named Oncology Scientific Advisor to Myriad Genetics May 31, 2023 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN Myriad Genetics Adds Folate Receptor Alpha to Precise™ Oncology Solutions Portfolio to Expand Treatment Options for Women Living with Ovarian Cancer May 24, 2023 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN Myriad Genetics Earns 2023 Great Place to Work Certification™ May 08, 2023 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN Myriad Genetics Reports First Quarter 2023 Financial Results; Achieves 10% Revenue Growth Year-Over-Year, the Second Consecutive Quarter of Double-Digit Year-Over-Year Revenue Growth; Raises Mid-Point of 2023 Revenue Guidance Range May 03, 2023 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN Myriad Genetics to Participate in BofA Securities Healthcare Conference May 02, 2023 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN Myriad Genetics to Release First Quarter Financial Results on May 3, 2023 April 26, 2023 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN 77% of Americans have used addictive behaviors or unhealthy coping mechanisms to manage their mental health, according to Myriad Genetics nationwide survey April 19, 2023 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN Myriad Genetics and Intermountain Precision Genomics Now Offer Solid Tumor Testing in All 50 States with Latest NY State Certification April 18, 2023 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN Myriad Genetics and SimonMed® Imaging Collaborate to Advance Precision Medicine with New Genetic Risk Assessment Program April 12, 2023 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN Illumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United States March 02, 2023 From Myriad Genetics, Inc. Via GlobeNewswire Tickers ILMN MYGN Myriad Genetics Applauds New Expanded Carrier Screening Practice Guidelines from NSGC March 01, 2023 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN Myriad Genetics Reports Fourth Quarter Financial Results; Fourth Quarter Revenue of $177.8 Million Grew 11% Year-Over-Year Driven by 16% Growth in Hereditary Cancer Volumes and 23% Growth in GeneSight® Volumes February 28, 2023 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN Myriad Genetics to Release Fourth-Quarter Financial Results on Feb. 28, 2023 February 22, 2023 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN Myriad Genetics to Participate in Upcoming Healthcare Conferences February 09, 2023 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN Myriad Genetics Highlights 2022 Research Findings that Help Advance More Accessible and Equitable Genetic Testing February 07, 2023 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN Myriad Genetics Applauds New Guidelines Recommending Screening for Chromosomal Abnormalities January 05, 2023 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN Myriad Genetics to Present at 41st Annual J.P. Morgan Healthcare Conference January 04, 2023 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN Myriad Genetics Hires Five Senior Leaders to Advance Commercial Growth Plans December 19, 2022 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN Myriad Genetics Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model December 08, 2022 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium Showcasing Advancements in Breast Cancer Risk Assessment and Treatment November 29, 2022 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.